Durability of the Mitroflow pericardial valve at ten years.
From 1983 to 1992, 366 patients received 407 Mitroflow pericardial valves. Mean age was 62 +/- 14 years. Average follow-up was 72 +/- 28 months. Total follow-up was 1,791 patient-years. Overall survival in all patients was 77.2% +/- 2.2% at 5 years and 56.2% +/- 6.4% at 10 years. Freedom from structural valve deterioration was 95% +/- 1.2% and 36.7% +/- 8.1% at 5 and 10 years for all valves, 96.9% +/- 1.3% and 39.2% +/- 9.8% for aortic valve replacement, and 91.7% +/- 3.2% and 36.4% +/- 10% for mitral valve replacement (p = not significant). The freedom from structural valve deterioration in patients older than 70 years of age was 100% and 93.9% +/- 5.8% at 5 and 10 years, respectively. At 10 years, linearized rate of thromboembolism was 0.73% +/- 0.2% per patient-year and freedom from valve-related mortality for all valves was 88.8% +/- 2.8%. The best indication for the implantation of a Mitroflow valve is mitral or aortic disease in patients more than 70 years of age.
Mazzucotelli
J P
JP
Department of Surgical Research, Centre National de la Recherche Scientifique, Unité de Recherche Associée 1431, Créteil, France.
Bertrand
P C
PC
Loisance
D Y
DY
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D001705:Bioprosthesis / Q000009:adverse effects / Q000401:mortality; D004696:Endocarditis / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011475:Prosthesis Failure; D012086:Reoperation; D015996:Survival Rate; D013923:Thromboembolism / Q000209:etiology